Results 301 to 310 of about 555,062 (342)

Neurotrophins as Potential Biomarkers for Active Disease and Poor Outcome in Pediatric Acute Lymphoblastic Leukemia. [PDF]

Cancers (Basel)
de Andrade KP, Michaelsen GL, Dutra LF, Marques RF, Benincasa DER, Portich JP, Loss JF, Gregianin LJ, Brunetto AT, Sinigaglia M, Roesler R, da Cunha Jaeger M, Land M, de Farias CB.   +13 more
europepmc   +1 more source

Insights on the Role of Sialic Acids in Acute Lymphoblastic Leukemia in Children. [PDF]

Int J Mol Sci
Radu KR, Baek KH.
europepmc   +1 more source

Prognostic value, biological role, and mechanisms of LCN2 in childhood acute lymphoblastic leukemia. [PDF]

Am J Cancer Res
Tang X, Li YY, Tan LJ, Gao J, Ma ZG, Guo X, Gu L, Liu HM.   +7 more
europepmc   +1 more source

Correction to "CD312 Promotes Pediatric Acute Lymphoblastic Leukemia Through GNA15 Mediated Non-Classical GPCR Signaling Pathway". [PDF]

J Cell Mol Med
europepmc   +1 more source

Acute Lymphoblastic Leukemia in Children. [PDF]

New England Journal of Medicine, 2015
The most common cancer in childhood is now curable in 90% of patients. Current efforts are focused on devising molecular-based therapy for the subsets of acute lymphoblastic leukemia that are most resistant to current therapy.
S. Hunger, C. Mullighan
semanticscholar   +5 more sources

Some of the next articles are maybe not open access.

Related searches:

Acute Lymphoblastic Leukemia

Hematology, 2002
AbstractThis is a comprehensive overview on the most recent developments in diagnosis and treatment of acute lymphoblastic leukemia (ALL).Dr. Dieter Hoelzer and colleagues give an overview of current chemotherapy approaches, prognostic factors, risk stratification, and new treatment options such as tyrosine kinase inhibitors and monoclonal antibodies ...
Dieter, Hoelzer, Nicola, Gökbuget, Oliver, Ottmann, Ching-Hon, Pui, Mary V, Relling, Frederick R, Appelbaum, Jacques J M, van Dongen, Tomasz, Szczepański   +7 more
openaire   +4 more sources

Acute Lymphoblastic Leukemia

2007
Acute lymphoblastic leukemia (ALL) comprises a heterogeneous group of disorders which originate from various important genetic lesions in B and T progenitor cells, including mutations that lead to stage-specific developmental arrest and those that impart the capacity for unlimited self-renewal, resulting in clonal expansion of immature progenitor cells
Biondi A., Scrideli C. A., Cazzaniga G.
openaire   +2 more sources

Acute Lymphoblastic Leukemia

Clinics in Laboratory Medicine, 2000
Over the last two decades, great strides have been made in the treatment of acute lymphoblastic leukemia (ALL). This progress has been paralleled by advances in diagnosis. In addition to morphology and cytochemistry, the diagnostic and prognostic importance of immunophenotypic and genetic features is becoming increasingly apparent. This article reviews
D C, Farhi, N S, Rosenthal
openaire   +2 more sources

Acute Lymphoblastic Leukemia

Pediatric Clinics of North America, 1997
Advances in the molecular and immunologic characterization of leukemic cells have greatly aided the diagnosis and risk assignment of ALL, as well as the monitoring of bone marrow samples for minimal residual disease. Currently, 75% of childhood cases have biologically and therapeutically relevant genetic abnormalities.
openaire   +3 more sources

Leukemia cutis in acute lymphoblastic leukemia

Journal of the American Academy of Dermatology, 1994
separating normal epidermis from a diffuse dermal infiltrate of lymphoid blast cells with round and regular nuclei, inconspicuous nucleoli, and scanty, moderately basophilic cytoplasm. Immunophenotype analysis revealed strong positivity for CD 10.The patient wastreated with methotrexate, teniposide, cytosine arabinoside, and local irradiation, and a ...
J.M. Forjaz de Lacerda, J. Forjaz de Lacerda, M. Lurdes Guerra, J. Alves do Carmo, Afonso Fernandes, L. Soares de Almeida   +5 more
openaire   +3 more sources